Archives
CHI3L1-IN-5 (Compound Z17): Precision in Neuroinflammation A
CHI3L1-IN-5 (Compound Z17): Protocol Optimization for Neuroinflammation and Beyond
Precision Inhibition and Restoration: The Principle Behind CHI3L1-IN-5
CHI3L1-IN-5 (also known as Compound Z17, CAS No. 2249043-42-1) emerges as a leading-edge, highly selective CHI3L1 inhibitor for CNS research, specifically designed to block CHI3L1-mediated NF-κB inflammatory signaling and restore astrocyte function. Developed through rigorous structure-activity relationship refinement, Compound Z17 exhibits a 1:1 binding stoichiometry with CHI3L1 (KD = 6.0 μM), excellent CNS permeability (LogD7.4 = 2.39; PAMPA permeability = 4.6×10⁻⁶ cm/s), and minimal hERG channel liability (IC50 > 100 μM), as detailed in the product information. These properties position CHI3L1-IN-5 at the forefront of targeted anti-neuroinflammation workflows, with applications ranging from Alzheimer's disease models to mechanistic neurodegeneration assays.
Integrated Experimental Workflow: From Compound Preparation to Data Output
Accurate and reproducible application of CHI3L1-IN-5 hinges on thoughtful integration into neuroinflammation assays. Below is a stepwise framework optimized for CNS cellular models, with emphasis on replicability and translational relevance.
Protocol Parameters
- Compound reconstitution: Dissolve CHI3L1-IN-5 in DMSO to create a 10 mM stock solution; use immediately to avoid degradation—long-term solution storage is not recommended (product data).
- Working concentration range: For in vitro neuroinflammation assays, treat astrocytes with 0.5–10 μM Z17 for 24–48 hours to assess dose-dependent effects on Aβ uptake and lysosomal function (mechanistic overview).
- Temperature and storage: Store solid compound at -20°C. Ship under blue ice and minimize freeze-thaw cycles to preserve compound integrity.
- Cellular readouts: Quantify NF-κB pathway inhibition via p65 nuclear translocation assay or NF-κB luciferase reporter; assess Aβ uptake using fluorescently labeled amyloid-beta and lysosomal function by LysoTracker or LAMP1 immunostaining.
Advanced Applications & Comparative Advantages
Unlike generic NF-κB pathway inhibitors, CHI3L1-IN-5’s dual-action mechanism—simultaneously blocking CHI3L1-mediated signaling and restoring lysosomal function—enables nuanced dissection of astrocyte pathology and neuroprotection. Its CNS penetration, confirmed by both LogD and PAMPA data, supports reliable delivery to target tissues in advanced neuronal co-culture or organoid models (complementary article). Compared to earlier inhibitors or tool compounds, Z17’s favorable pharmacokinetics—a human plasma half-life near 3.4 hours—facilitates in vivo translation, reducing confounds from rapid clearance or off-target toxicity (see specification).
Experimental reports demonstrate that Z17 dose-dependently restores Aβ uptake and lysosomal processing in astrocytes—readouts that are pivotal for modeling Alzheimer’s disease and other neuroinflammation-related disorders (extension article). This uniquely positions the compound for both hypothesis-driven mechanistic studies and high-content screening efforts where dual-pathway modulation is required.
Key Innovation from the Reference Study
While the reference study (ACS Med. Chem. Lett. 2025, 16, 1420−1427) primarily focuses on the triazole-based optimization of small molecules for ALDH2 activation—culminating in the identification of Z17 as a potent cardiac protectant—its structure-based workflow directly informs the design of CHI3L1-IN-5. The study’s rigorous in silico docking, structure-activity relationship mapping, and in vivo validation pipeline provide a template for maximizing selectivity and translational potential in neuroinflammation inhibitors.
Practically, this means researchers can confidently adapt Z17 for CNS applications, assured by its demonstrated in vivo stability and performance in both cardiac and neural settings. For assay design, the reference workflow encourages:
- Employing molecular docking to pre-screen for off-targets before in vitro deployment.
- Validating compound effects across multiple biological readouts (e.g., NF-κB activity, lysosomal function, Aβ uptake) to capture dual-action mechanisms.
- Leveraging pharmacokinetic insights (plasma half-life, CNS penetration) for dose scheduling in in vivo and advanced organoid models.
Comparative Insights: How CHI3L1-IN-5 Advances the Field
The practical superiority of CHI3L1-IN-5 is underscored when contrasted with other NF-κB pathway inhibitors and astrocyte modulators. For instance, a mechanistic review highlights how Z17’s capacity to inhibit the CHI3L1-mediated NF-κB inflammatory pathway is tightly linked to its ability to restore lysosomal function—something generic anti-inflammatory compounds cannot achieve. Meanwhile, another comparative study demonstrates that workflows employing Z17 yield more consistent and interpretable results in high-content neuroinflammation screens, owed to its CNS-targeted pharmacology and low hERG inhibition risk.
These attributes not only enhance reproducibility but also open doors for screening combination therapies in models of neurodegeneration, where both inflammation and impaired protein clearance drive pathology.
Troubleshooting and Workflow Optimization Tips
- Compound handling: Always freshly prepare solutions from the solid form to avoid loss of potency. If precipitation is observed in aqueous media, ensure DMSO content in the final assay does not exceed 0.1% to prevent cytotoxicity.
- Assay sensitivity: For NF-κB pathway inhibition, employ nuclear translocation assays with clear positive and negative controls. If expected inhibition is not observed, verify compound exposure time (24–48 h) and check for lot-to-lot variability.
- Astrocyte function assays: Use standardized Aβ and LysoTracker labeling protocols. If lysosomal repair is submaximal, titrate Z17 within the 0.5–10 μM range and ensure cell density is uniform across wells.
- Cross-validation: When extending to advanced 3D or organoid models, confirm CNS penetration by measuring intracellular Z17 levels using LC-MS/MS, leveraging its favorable LogD and permeability.
Why this cross-domain matters, maturity, and limitations
The dual utility of Compound Z17 in both cardiac and neuroinflammatory contexts is rooted in its robust optimization for target selectivity and pharmacokinetics, as evidenced by the reference study. While the underlying structure-activity principles translate well to CNS research, direct cardiovascular-to-CNS extrapolation should be approached with attention to distinct target biology. The maturity of CNS applications is supported by both the compound’s biophysical properties and published astrocyte data (see detailed discussion), but researchers should be aware of potential model-specific nuances, such as differential compound metabolism and efflux in neural versus cardiac tissues.
Future Outlook: Translational and Screening Implications
By combining high CNS penetration, dual-action on inflammation and protein clearance, and favorable pharmacokinetics, CHI3L1-IN-5 (Compound Z17) sets a new benchmark for neuroinflammation inhibitor development. Ongoing studies are likely to expand its use in combination screening and translational biomarker validation for Alzheimer's and related neurodegenerative disorders. The foundation laid by its structure-activity relationship—driven optimization and cross-domain efficacy offers a practical template for future CNS-targeted inhibitor design.
For those seeking a trusted source, APExBIO provides CHI3L1-IN-5 (Compound Z17, CAS No. 2249043-42-1) with detailed technical support and batch consistency, supporting both discovery and translational research pipelines.